UK and US Stem Cell Banks team up to share expertise
Plan to drive forward stem cell research
The UK and UMASS Stem Cell Banks have signed a Memorandum of Understanding (MOU) that will outline plans for cooperation in a variety of stem cell areas including the delivery of stem cell lines for clinical use.
The agreement outlines plans for the two stem cell banks to work together to ensure that best practice and high standards in stem cell banking are employed at both sites. They will also develop international training events for scientists involved in stem cell research.
Stem cells are the body's 'master cells', with the potential to become many different types of tissue. It is hoped that stem cell treatments may be used in future to help people with Parkinson's disease, diabetes or multiple sclerosis by repairing and replacing diseased and damaged body tissue.
The UK Stem Cell Bank, funded by the Medical Research Council and the Biotechnology and Biological Sciences Research Council, is a repository for human cell lines, derived from stem cells. It also holds new and existing adult, foetal and embryonic stem cell lines. Stem cell lines are provided only to accredited researchers to ensure the safe and ethical development of any potential stem cell therapy.
Dr Stephen Inglis, director of HPA's NIBSC said: ‘International co-operation is vital in this fast moving field and we expect that the partnership will accelerate the development of important new therapies, as well as keeping the UK at the forefront of stem cell research.’
Joseph Laning, senior director of the Human Stem Cell Bank and Registry at UMASS Medical School, added: ‘Both banks share common goals and needs. Working in concert allows us to develop strategies that will shape stem cell production, characterisation, banking and distribution in a dynamic field. Each bank brings its own unique attributes to bear in a way that will enhance our influence in the field.’
You may also like
Research & Development
Cirena and Epigenica launch technologies to accelerate genome editing and epigenomic research
Read moreTwo life sciences companies have announced new technologies designed to address long-standing bottlenecks in genome editing and epigenomic analysis, offering faster timelines and improved reproducibility for researchers in academia and industry
Trending Articles
Upcoming event
You may also like
Research & Development
Cirena and Epigenica launch technologies to accelerate genome editing and epigenomic research
Two life sciences companies have announced new technologies designed to address long-standing bottlenecks in genome editing and epigenomic analysis, offering faster timelines and improved reproducibility for researchers in academia and industry
Research & Development
AdvanCell partners with 48Hour Discovery on peptide-based lead-212 radiotherapeutic
The pair will develop a novel peptide-based Lead-212 radiotherapeutic targeting a gastrointestinal cancer with significant unmet need, strengthening AdcanCell's pipeline of differentiated targeted alpha therapies
Research & Development
Baseline Therapuetics launches to advance GLP-1 Phase III Programme in Alcohol Use Disorder
The clinical-stage biotech has launched to progress BT-001, a once-weekly GLP-1 receptor agonist, into FDA-aligned Phase III trials for alcohol use disorder, with studies planned to begin in 2026
Research & Development
Researchers identify early signs of Parkinson's in the blood
Researchers at Chalmers University of Technology have identified early-stage Parkinson’s disease biomarkers detectable in blood, revealing a limited diagnostic window that could enable screening and earlier intervention years before motor symptoms appear
Research & Development
iXCells and Rosebud Biosciences pair up to advance organoid-based models for rare diseases
The expansion of iXCells’ iPSCore platform with integration of 3D human organoid expertise will enable evaluation of drug toxicity and tissue-specific responses, meeting growing demand for scalable, patient-relevant human models to support translational decision-making in drug development